60
600535.SHG Tasly Pharmaceutical Group Co Ltd
- Market cap
- CNY 21.4B
- P/E
- 17.7x
- P/B
- 1.67x
- ROE
- 11.4%
- Dividend yield
- 2.86%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 600535.SHG undervalued?
Graham number600535.SHG trades 14.5% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Tasly Pharmaceutical Group Co Ltd fundamental analysis
No fundamental analysis for Tasly Pharmaceutical Group Co Ltd yet.
Tasly Pharmaceutical Group Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Tasly Pharmaceutical Group Co Ltd
Tasly Pharmaceutical Group Co., Ltd, together with its subsidiaries, engages in the research, development, production, and sale of pharmaceuticals in China. The company offers prescription drugs covering various therapeutic areas, including cardiovascular-cerebrovascular, tumor immunity, digestion and metabolism, and neuroscience; over-the-counter drugs; modern TCM; biological drugs; and chemical drugs. It also engages in medical instruments, agriculture, and chain drugstore…
Full company profileTasly Pharmaceutical Group Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Tasly Pharmaceutical Group Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 13.9B | 16.1B | 18.0B | 19.0B | 13.6B | 7.95B | 8.64B | 8.67B | 8.50B | 8.24B | 8.10B |
| Gross Profit | 5.09B | 5.83B | 6.51B | 5.94B | 5.46B | 5.27B | 5.49B | 5.79B | 5.69B | 5.51B | 5.55B |
| Operating Income | 1.47B | 1.74B | 1.94B | 1.34B | 1.47B | 2.73B | -160M | 1.23B | 1.08B | 1.35B | 1.93B |
| EBITDA | 2.04B | 2.40B | 2.81B | 2.18B | 2.29B | 3.21B | 336M | 1.81B | 1.53B | 1.74B | 1.71B |
| Net Income | 1.18B | 1.38B | 1.55B | 1.00B | 1.13B | 2.36B | -264M | 1.07B | 956M | 1.11B | 1.47B |
| EPS | 0.78 | 0.91 | 1.02 | 0.66 | 0.75 | 1.57 | -0.18 | 0.72 | 0.64 | 0.74 | 0.98 |
| Balance Sheet | |||||||||||
| Total Assets | 17.1B | 21.5B | 25.2B | 24.0B | 16.5B | 16.5B | 16.4B | 16.7B | 15.0B | 15.3B | 15.1B |
| Total Liabilities | 8.92B | 12.6B | 14.0B | 12.2B | 4.11B | 3.23B | 3.80B | 4.02B | 2.87B | 2.79B | 2.02B |
| Shareholders' Equity | 7.96B | 8.65B | 10.5B | 11.1B | 12.0B | 13.0B | 12.4B | 12.4B | 11.9B | 12.4B | 12.9B |
| Cash & Short-term Investments | 1.33B | 1.50B | 3.14B | 1.95B | 2.12B | 3.79B | 4.23B | 4.75B | 3.52B | 2.83B | 970M |
| Total Debt | 3.19B | 8.24B | 9.55B | 8.09B | 2.79B | 1.70B | 2.18B | 2.96B | 1.02B | 1.48B | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 1.15B | -823M | 1.49B | 1.68B | 1.79B | 2.80B | 2.29B | 2.58B | 2.01B | 1.42B | - |
| Capital Expenditure | 525M | 512M | 780M | 731M | 409M | 572M | 403M | 669M | 565M | 381M | 310M |
| Free Cash Flow | 629M | -1.33B | 714M | 949M | 1.38B | 2.23B | 1.88B | 1.91B | 1.45B | 1.04B | 1.46B |
| Ratios | |||||||||||
| ROE | 14.8% | 15.9% | 14.7% | 9.0% | 9.4% | 18.2% | -2.1% | 8.7% | 8.0% | 8.9% | 11.4% |
| ROA | 6.9% | 6.4% | 6.1% | 4.2% | 6.8% | 14.3% | -1.6% | 6.4% | 6.4% | 7.2% | 9.8% |
| Net Profit Margin | 8.4% | 8.6% | 8.6% | 5.3% | 8.3% | 29.7% | -3.1% | 12.3% | 11.2% | 13.4% | 18.2% |
| Debt to Equity | 0.40x | 0.95x | 0.91x | 0.73x | 0.23x | 0.13x | 0.18x | 0.24x | 0.09x | 0.12x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Tasly Pharmaceutical Group Co Ltd dividends
- Dividend yield
- 2.86%
- Forward dividend
- 0.34 CNY
- Payout ratio
- 55.4%
- Ex-dividend date
- Oct 15, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 613M | 0.41 | 55.4% |
| 2024 | CNY 1.04B | 0.70 | 109.1% |
| 2023 | CNY 493M | 0.33 | 46.0% |
| 2022 | CNY 554M | 0.38 | - |
| 2021 | CNY 610M | 0.41 | 25.9% |
| 2020 | CNY 498M | 0.33 | 44.2% |
| 2019 | CNY 452M | 0.30 | 45.2% |
| 2018 | CNY 860M | 0.57 | 55.7% |
| 2017 | CNY 930M | 0.61 | 67.6% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.4:1 on Jun 5, 2018.
Who owns Tasly Pharmaceutical Group Co Ltd
- Insiders 52.89%
- Institutions 6.72%
- Public & others 40.39%
- Shares outstanding 1.49B
- Free float 737M
Tasly Pharmaceutical Group Co Ltd company profile
- Company name
- Tasly Pharmaceutical Group Co Ltd
- Ticker
- 600535.SHG
- ISIN
- CNE000001C81
- Exchange
- Shanghai Stock Exchange
- Listed since
- Aug 8, 2002
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 10,563
- Fiscal year end
- December
- Address
- No. 2 Pujihe East Road, Tianjin, China, 300410
- Phone
- 86 22 2673 6999
- Website
- taslypharma.com
About Tasly Pharmaceutical Group Co Ltd
Tasly Pharmaceutical Group Co., Ltd, together with its subsidiaries, engages in the research, development, production, and sale of pharmaceuticals in China. The company offers prescription drugs covering various therapeutic areas, including cardiovascular-cerebrovascular, tumor immunity, digestion and metabolism, and neuroscience; over-the-counter drugs; modern TCM; biological drugs; and chemical drugs. It also engages in medical instruments, agriculture, and chain drugstore activities. The company was formerly known as Tianjin Tasly Pharmaceutical Co., Ltd. and changed its name to Tasly Pharmaceutical Group Co., Ltd in May 2012. Tasly Pharmaceutical Group Co., Ltd was founded in 1994 and is headquartered in Tianjin, China.
Tasly Pharmaceutical Group Co Ltd management
8- Ms. Jie WeiCFO & Head of Accounting · born 1977
- Mr. Ai Chun JuDeputy General Manager · born 1974
- Mr. Shunnan ZhangDeputy General Manager · born 1973
- Mr. Shui Ping ZhouDeputy GM & Director · born 1972
- Ms. Zhen WangDeputy General Manager · born 1975
- Mr. Yiming WangDeputy General Manager · born 1980
- Mr. Yu JieSecretary & Deputy GM · born 1975
- Mr. Kai XiGM, Deputy Party Secretary & Director · born 1978